JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive: Targeting of JAK2 with small molecule inhibitors in combination with chemotherapy may be one such therapeutic approach, given the remarkable success of TKIs for the treatment of CML (Ali, 2016).